These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 26929611)

  • 21. A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
    Tanaka H; Taima K; Morimoto T; Tanaka Y; Itoga M; Nakamura K; Hayashi A; Kumagai M; Yasugahira H; Mikuniya M; Okudera K; Takanashi S; Tasaka S
    BMC Cancer; 2017 Oct; 17(1):683. PubMed ID: 29037236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
    J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer.
    Lammers PE; Lu B; Horn L; Shyr Y; Keedy V
    Oncologist; 2015 May; 20(5):491-2. PubMed ID: 25845992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
    Yoshimura N; Sawa K; Nakai T; Matsumoto Y; Mitsuoka S; Kimura T; Asai K; Yana T; Kawaguchi T; Hirata K
    Am J Clin Oncol; 2021 Dec; 44(12):613-618. PubMed ID: 34753884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer.
    Noronha V; Patil VM; Joshi A; Prabhash K
    Indian J Cancer; 2013; 50(2):122-7. PubMed ID: 23979203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.
    Langer CJ; Hirsh V; Okamoto I; Lin FJ; Wan Y; Whiting S; Ong TJ; Renschler MF; Botteman MF
    Br J Cancer; 2015 Jun; 113(1):20-9. PubMed ID: 26035702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
    Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
    Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
    Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M
    BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
    Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S
    Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
    Langer CJ; Hirsh V; Ko A; Renschler MF; Socinski MA
    Clin Lung Cancer; 2015 Mar; 16(2):112-20. PubMed ID: 25572008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
    Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
    Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
    Soejima K; Naoki K; Ishioka K; Nakamura M; Nakatani M; Kawada I; Watanabe H; Nakachi I; Yasuda H; Satomi R; Nakayama S; Yoda S; Ikemura S; Terai H; Sato T; Ohgino K; Arai D; Tani T; Kuroda A; Nishino M; Betsuyaku T
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):513-9. PubMed ID: 25563719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin.
    Hirsh V; Wan Y; Lin FJ; Margunato-Debay S; Ong TJ; Botteman M; Langer C
    Clin Lung Cancer; 2018 Sep; 19(5):401-409.e4. PubMed ID: 29903552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
    Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
    Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.
    Gridelli C; Chen T; Ko A; O'Brien ME; Ong TJ; Socinski MA; Postmus PE
    Drug Des Devel Ther; 2018; 12():1445-1451. PubMed ID: 29872267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
    Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y
    Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.